CB Pharma Acquisition Corp.
Liquidated 2018-08-10- CIK 1619551
- CNLM
- IPO 2014-12-12
- $42.8M trust
- 155 filings
- IPO Size
- $42M
- raised at the IPO
- Trust
- $42.8M
- as of 2014-12-18
- Current Status
- Failed
- from its latest filing
- IPO Year
- 2014
- year it listed
Filings, by quarter
155 filings over 19 quarters; violet bars carry a milestone
- 14 Q3: 1 filing
- 14 Q4: 29 filings
- 15 Q1: 6 filings
- 15 Q2: 1 filing
- 15 Q3: 1 filing
- 15 Q4: 6 filings
- 16 Q1: 6 filings
- 16 Q2: 31 filings
- 16 Q3: 1 filing
- 16 Q4: 10 filings
- 17 Q1: 11 filings
- 17 Q2: 1 filing
- 17 Q3: 8 filings
- 17 Q4: 10 filings
- 18 Q1: 19 filings
- 18 Q2: 7 filings
- 18 Q3: 4 filings
- 18 Q4: 1 filing
- 19 Q1: 2 filings
- S-1 filed 14 Q3
- IPO 14 Q4
- Liquidated 18 Q3
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
CB Pharma Acquisition Corp. is a blank-check company formed to combine with a business. Its initial search focus is specialty pharma and generic drug industries, including drug rights or companies holding such rights.
Investment Focus
Biopharmaceuticals
Geographic Focus
North America, Europe, South America, Asia
Key Information
As the filings state it
- IPO Date
- 2014-12-12
- Total Redemptions
- $29.5M
- Jurisdiction of Incorporation
- Cayman Islands
- SIC
- 6770
- Failed Date
- 2018-08-10
- SPAC Ticker
- CNLM
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
Led by Lindsay A. Rosenwald, a life-sciences investment and pharmaceutical executive, and Michael S. Weiss, a biotechnology executive and investor; other directors bring biologics operations, investment, legal, finance and clinical medicine experience.